| Abstrakt: |
These studies show that the potent, non-specific, protein kinase inhibitor, staurosporine, disrupts Ca2+ homeostasis in cultured bovine adrenal chromaffin cells. Staurosporine treatment reduces basal and A23187-stimulated catecholamine release from chromaffin cells, but does not inhibit activated Ca2+ influx. Furthermore, pretreatment with staurosporine also reduces Ca(2+)-stimulated catecholamine release from digitonin-permeabilized cells (t1/2, 40.6 min; IC50, 66.0 nm). However, staurosporine does not inhibit the rise in intracellular Ca2+ ([Ca2+]i) in response to nicotine stimulation as measured by fura-2 photometry. These studies demonstrate that staurosporine interferes with the secretory process at some step at or after the rise in [Ca2+]i in adrenal chromaffin cells. Examination of the effects of staurosporine on 45Ca2+ movement shows that staurosporine produces a slowly developing basal 45Ca2+ accumulation; after 30 min no significant change is observed, but by 120 min, 45Ca2+ accumulation is increased by 29.5%. Thapsigargin and 2,5-di-(tert-butyl)-1,4-benzohydroquinone (tBHQ), inhibitors of Ca(2+) ATPases, were used to determine whether staurosporine induced 45Ca2+ accumulation results from sequestration of 45Ca2+ within intracellular stores. While thapsigargin has no significant effect, concomitant treatment with tBHQ prevents the increase in 45Ca2+ uptake associated with staurosporine treatment. Therefore, the tBHQ-sensitive Ca2+ store, but not the thapsigargin/inositol 1,4,5-triphosphate-sensitive Ca2+ store, appears to be staurosporine-sensitive. Overall, these studies indicate that staurosporine reduces catecholamine release by interfering with Ca2+ homeostasis. Furthermore, this work suggests that a staurosporine-sensitive phosphoprotein(s) is involved with the regulation of Ca2+ homeostasis in bovine adrenal chromaffin cells. |
Full Text from ScienceDirect